Moleculin Biotech Inc.
NASDAQ
Closed
Jul 29, 2026
Day's Range
1.3452 wk Range
1.34Key Statistics
Symbol
MBRX
Name
Moleculin Biotech Inc.
Currency
USD
Exchange
NASDAQ
High
2.16
Low
1.34
Open
‪2.13‬
Last
‪1.35‬
Market Cap
15.47M
Pe Ratio
‪-0.04‬
Volume
337.94K
Average Volume
106.64K
Dividend Yield
‪0.00%‬
Change
-0.84
Percent Change
-38.13
Timestamp
2026-07-29
Close
1.355
Today Range Start
‪1.34‬
Today Range End
‪2.16‬
52 Week Range Start
‪1.34‬
52 Week Range End
‪18.75‬
Type
Stocks
Country
United States
Compliance - MBRX - Moleculin Biotech Inc.
Compliance
Status
NON_COMPLIANT
Report Date
2025-02-17
Business Screen
COMPLIANT
Financial Screen
NON_COMPLIANT
Compliant Revenue
‪97.00%‬
Non Compliant Revenue
‪2.00%‬
Questionable Revenue
‪1.00%‬
Securities To Market Cap Ratio
‪50.00%‬
Debt To Market Cap Ratio
‪90.00%‬
Historical Data - MBRX - Moleculin Biotech Inc.
Historical Data
Market Cap - MBRX - Moleculin Biotech Inc.
Market Cap
2026-07-28
15.47M
2026-07-27
15.47M
2026-07-24
14.97M
2026-07-23
14.69M
2026-07-22
14.83M
2026-07-21
15.18M
2026-07-20
15.11M
2026-07-17
14.83M
2026-07-16
15.33M
2026-07-15
16.32M
Splits - MBRX - Moleculin Biotech Inc.
Splits
2025-12-01
1-for-25 split (25)
Earnings - MBRX - Moleculin Biotech Inc.
Earnings
Balance Sheet - MBRX - Moleculin Biotech Inc.
Balance Sheet
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
 Assets | 22.12M | 16.92M | 38.21M | 57.42M | 84.09M | 29.03M |
| Liabilities | 7.12M | 10.94M | 12.14M | 5.23M | 5.09M | 11.27M |
| Shareholders Equity | 15M | 5.97M | 26.07M | 52.19M | 78.99M | 17.76M |
Cash Flow - MBRX - Moleculin Biotech Inc.
Cash Flow
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Operating Activities | - | - | - | - | - | - |
| Investing Activities | - | - | - | - | - | - |
| Financing Activities | - | - | - | - | - | - |
| End Cash Position | 8.87M | 4.27M | 23.55M | 43.14M | 70.90M | 15.17M |
| Income Tax Paid | - | - | - | - | 15K | 24K |
| Interest Paid | - | - | - | - | 0 | 0 |
| Free Cash Flow | -22.73M | -23.87M | -24.22M | -27.70M | -18.97M | -18.14M |
Income Statement - MBRX - Moleculin Biotech Inc.
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Sales | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Goods | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| Operating Expense | - | - | - | - | - | - |
| Operating Income | -25.10M | -26.64M | -29.63M | -30.64M | -22.96M | -19.74M |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | -8.56M | 4.32M | -1.50M | 1.37M | 6.76M | 2.37M |
| Pre Tax Income | -33.56M | -21.76M | -29.76M | -29.02M | -15.89M | -17.35M |
| Income Tax | - | - | - | - | - | 0 |
| Net Income | -33.56M | -21.76M | -29.76M | -29.02M | -15.89M | -17.35M |
| EPS Basic | -28.42 | -158 | -15.14535 | -15.15 | -8.85 | -26.4 |
| EPS Diluted | -28.42 | -158 | -15.14535 | -15.15 | -8.85 | -26.4 |
| Basic Shares Outstanding | 1.18M | 137.71K | 1.96M | 1.90M | 1.79M | 656.37K |
| Diluted Shares Outstanding | 1.18M | 137.71K | 1.96M | 1.90M | 1.79M | 656.37K |
| Ebit | -25.10M | -26.64M | -29.63M | -30.64M | -22.96M | -19.74M |
| Ebitda | -16.47M | -30.80M | -28.46M | -31.84M | -29.53M | -21.88M |
| Net Income Continuous Operations | -33.56M | -21.76M | -29.76M | -29.02M | -15.89M | -17.35M |
| Minority Interests | - | - | - | - | - | - |
| Preferred Stock Dividends | 104K | - | - | - | - | - |
Recommendations - MBRX - Moleculin Biotech Inc.
Recommendations
Profile - MBRX - Moleculin Biotech Inc.
Profile
Mic Code
XNCM
Sector
Healthcare
Industry
Biotechnology
Employees
17
Moleculin Biotech Inc. is a clinical-stage pharmaceutical company that primarily focuses on the development of oncology drug candidates. Based in Houston, Texas, the company concentrates its efforts on addressing unmet medical needs related to cancer. Moleculin Biotech is notable for its diverse pipeline of drug candidates, which includes small molecules targeting key biological pathways involved in cancer cell proliferation and survival. The company leverages its novel technologies, such as its Immune/Transcription Modulary Technology, to develop potential treatments that can be more effective and less toxic than existing therapies. Moleculin Biotech's research and developments are particularly influential within the biotechnology and pharmaceutical sectors, contributing to advancements in cancer treatment and offering hope for new therapeutic options. Through its innovative approach to drug development, Moleculin Biotech Inc. plays a significant role in the broader scientific and medical community, aiming to translate groundbreaking research into practical treatments that can improve patient outcomes.
Profile Details
Type
Common Stock
Ceo
Mr. Walter V. Klemp
Address
5300 Memorial Drive
City
Houston
State
TX
Zip
77007
Country
United States
Phone
713 300 5160
